Skip to content

Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury

Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05434286
Enrollment
75
Registered
2022-06-28
Start date
2021-12-15
Completion date
2023-06-15
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute-On-Chronic Liver Failure, AKI, Cirrhosis, Liver, Hepatorenal Syndrome, Refractory Ascites

Brief summary

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately. We will assess IVC dynamics, LV systolic function \[LV ejection fraction (EF) & cardiac output (CO)\], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and ACLF with hepatorenal syndrome-acute kidney injury (HRS-AKI).

Interventions

POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Cirrhosis of any Etiology * Patient with acute kidney injury meeting HRS-AKI criteria

Exclusion criteria

* Hepatocellular carcinoma * Patients with active variceal bleeding * HIV or severe immunocompromised state * Chronic kidney disease (CKD) on renal replacement therapy (RRT), * Previous transjugular intra hepatic portosystemic shunt (TIPS) * Porto-pulmonary hypertension, * Coronary artery disease * Congenital or valvular heart disease * Prosthetic cardiac valves

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with Non-Response in HRS-AKIDay 7Non-responder is defined if the sCr did not decrease or increased from the baseline.
Cardiac output measurement by echocardiographyDay 0, Day 2, Day 7.Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0 and 48 hours after enrollment. The cardiac output at 7 days after enrollment will also be documented. he Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000
IVC size and collapsibility changesDay 0.IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Number of patients with Complete Response in HRS-AKIDay 7Complete response is defined as a reversal in AKI with a final serum Creatinine (sCr) value of ≤ 0.3 mg/dL of the baseline.
Number of patients with Partial Response in HRS-AKIDay 7Partial response is defined as regression in the stage of AKI with a final sCr \> 0.3 mg/dL above the baseline.

Secondary

MeasureTime frame
Change in NT Pro brain natriuretic peptide (BNP) levelDay 0 and Day 7
Change in plasma renin activity levelDay 0 and Day 7
Change in Galectin-3 levelDay 0 and Day 7
Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) levelDay 0 and Day 7

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026